Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 7/2022

27-04-2022 | Ovarian Cancer | Review Article

The roles and limitations of bevacizumab in the treatment of ovarian cancer

Authors: Hidekatsu Nakai, Noriomi Matsumura

Published in: International Journal of Clinical Oncology | Issue 7/2022

Login to get access

Abstract

Bevacizumab, an anti-VEGF antibody, targets mainly tumor blood vessels and exerts a cytostatic antitumor effect. In primary ovarian cancer, bevacizumab is used for 15 months, but its effect on progression-free survival disappears after 2 years and does not prolong overall survival. And in the treatment of primary ovarian cancer, there is no evidence that bevacizumab increases the intratumor concentration of chemotherapy and enhances response rates. On the other hand, bevacizumab is not affected by resistance mechanisms to chemotherapeutic agents or poly(ADP-ribose) polymerase (PARP) inhibitors. In the era of using PARP inhibitors for primary ovarian cancer, bevacizumab will become a molecularly targeted drug that will play a central role in chemo-refractory and recurrent ovarian cancer.
Literature
1.
Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2783CrossRef
2.
Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496CrossRef
3.
4.
5.
Bais C, Mueller B, Brady MF et al (2017) Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst 109:djx066CrossRef
6.
Tewari KS, Burger RA, Enserro D et al (2019) Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol 37:2317–2328CrossRef
7.
Oza AM, Cook AD, Pfisterer J et al (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16:928–936CrossRef
8.
Tewari KS, Sill MW, Long HJ et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734–743CrossRef
9.
Tewari KS, Sill MW, Penson RT et al (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390:1654–1663CrossRef
10.
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRef
11.
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676CrossRef
12.
Pfister J, Joly F, Kristensen G et al (2021) Optimal treatment duration of bevacizumab combined with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer: A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890). J Clin Oncol 39(Suppl 15):5501CrossRef
13.
Tong RT, Boucher Y, Kozin SV et al (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731–3736CrossRef
14.
15.
Roman Rouzier R, Gouy S, Selle F et al (2017) Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer 70:133–142CrossRef
16.
Röhrig F, Vorlová S, Hoffmann H et al (2017) VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. Oncogene 36:1–12CrossRef
17.
Norquist BM, Brady MF, Harrell MI et al (2018) Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777–783CrossRef
18.
Ferriss JS, Java JJ, Bookman MA et al (2015) Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecol Oncol 139:17–22CrossRef
19.
Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302–1308CrossRef
20.
Poveda AM, Selle F, Hilpert F et al (2015) Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol 33:3836–3838CrossRef
21.
Simon T, Gagliano T, Giamas G (2017) Direct effects of anti-angiogenic therapies on tumor cells: VEGF signaling. Trends Mol Med 23:282–292CrossRef
22.
Pasquier E, SHonoré S, Braguer D (2006) Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Updat 9:74–86CrossRef
23.
Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045CrossRef
24.
Coleman RL, Brady MF, Herzog TJ et al (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779–791CrossRef
25.
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323–3329CrossRef
26.
Pfisterer J, Shannon CM, Baumann K et al (2020) Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol 21:699–709CrossRef
27.
Shoji T, Enomoto T, Abe M et al (2022) Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023. Cancer Sci 113:240–250CrossRef
28.
Pignata S, Lorusso D, Joly F et al (2021) Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol 22:267–276CrossRef
29.
Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29–37CrossRef
30.
Gu S, Lheureux S, Sayad A et al (2021) Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc Natl Acad Sci USA 118:e2026663118CrossRef
31.
Friedlander M, Matulonis U, Gourley C et al (2018) Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 119:1075–1085CrossRef
32.
Cecere SC, Giannone G, Salutari V et al (2020) Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecol Oncol 156:38–44CrossRef
33.
34.
Pujade-Lauraine E, Selle F, Scambia G et al (2021) Maintenance olaparib rechallenge in patients with ovarian carcinoma previously treated with a PARP inhibitor: phase IIIb OReO/ENGOT Ov-38 trial. Ann Oncol 32(suppl_5):S1283–S1346
35.
Patch AM, Christie EL, Etemadmoghadam D et al (2015) Whole-genome characterization of chemoresistant ovarian cancer. Nature 521:489–494CrossRef
36.
Lheureux S, Oaknin A, Garg S et al (2020) EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin Cancer Res 26:4206–4215CrossRef
Metadata
Title
The roles and limitations of bevacizumab in the treatment of ovarian cancer
Authors
Hidekatsu Nakai
Noriomi Matsumura
Publication date
27-04-2022
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology / Issue 7/2022
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-022-02169-x

Other articles of this Issue 7/2022

International Journal of Clinical Oncology 7/2022 Go to the issue

Original Article

Performance of Idylla™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer

Original Article

Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer

Invited Review Article

New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma

Original Article

The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis

Original Article

Efficacy of EUS-guided celiac plexus neurolysis in combination with EUS-guided celiac ganglia neurolysis for pancreatic cancer-associated pain: a multicenter prospective trial

Original Article

Establishment and validation of a nomogram for predicting potential lateral pelvic lymph node metastasis in low rectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits